PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of archdischArchives of Disease in ChildhoodVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Arch Dis Child. Sep 2006; 91(9): 753–761.
Published online May 11, 2006. doi:  10.1136/adc.2006.093997
PMCID: PMC2082926
Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis
J Thornton, D M Ashcroft, M Z Mughal, R A Elliott, T W O'Neill, and D Symmons
J Thornton, T W O'Neill, D Symmons, Arthritis Research Campaign Epidemiology Unit, Division of Epidemiology and Health Sciences, University of Manchester, UK
D M Ashcroft, R A Elliott, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK
M Z Mughal, Department of Paediatric Medicine, Saint Mary's Hospital for Women & Children, Manchester, UK
Correspondence to: Prof. D Symmons
Arthritis Research Campaign Epidemiology Unit, Division of Epidemiology and Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK; deborah.symmons@manchester.ac.uk
Accepted April 26, 2006.
Aims
To evaluate the currently available evidence for the effectiveness of bisphosphonates in children with low bone mineral density (BMD) and fragility fractures associated with juvenile idiopathic arthritis (JIA), and the safety of bisphosphonates in JIA and other conditions.
Methods
Literature databases were searched using a structured search strategy. The effectiveness review included any studies of children with JIA treated with bisphosphonates. The safety review also included studies of osteogenesis imperfecta. Quantitative data analysis was not undertaken because of the heterogeneity of the studies; findings were summarised using tables and narrative synthesis.
Results
Ninety four studies were identified. Sixteen studies (78 JIA children) were included in the effectiveness review: one randomised controlled trial, three controlled cohort studies, 11 case series, and one case report. At baseline, children had low BMD below the expected values for age and sex matched children. In all studies, treatment with bisphosphonates increased BMD compared with baseline: the mean percentage increase in spine BMD ranged from 4.5% to 19.1%. Overall, studies were heterogeneous and of variable quality. A total of 59 papers were included in the safety review; treatment durations were up to three years. The most common side effect was a flu‐like reaction with intravenous treatment. This occurred during the first infusion and was transient; the symptoms were managed with paracetamol and did not occur during subsequent cycles.
Conclusions
Bisphosphonates are a promising treatment for low BMD and fragility fractures in children with JIA. However, the quality of the current evidence is variable and better studies are needed to more clearly assess their role.
Keywords: juvenile idiopathic arthritis, bisphosphonates, systematic review, fragility fractures
Fragility fractures are well recognised serious long term complications of juvenile idiopathic arthritis (JIA) and are associated with considerable morbidity and impaired quality of life. In a study using the UK General Practice Research Database, there was a statistically significantly greater number of fractures in subjects with childhood onset arthritis compared with healthy controls.1 Adults with a history of JIA have reduced bone mineral density and increased bone turnover compared with healthy control subjects.2,3
Bone mineral content (BMC) and bone mineral density (BMD), which are the quantifiable parameters of bone strength in vivo, account for approximately 60% of the total bone strength or the resistance to fracture.4 Dual energy x ray absorptiometry (DXA) is the most commonly used technique for measurement of BMC and BMD in children and adults. DXA calculates density from the scanned area of bone and estimates areal BMD (aBMD) as g/cm2. In postmenopausal Caucasian women, the World Health Organization arbitrarily defined osteopenia as those with an aBMD between more than 1 standard deviation (SD) but less than 2.5 SD and osteoporosis as aBMD of more than 2.5 SD below the mean for young adult women.5 In adults, the risk of fracture appears to double for each 1 SD decrease in BMD.6 There is no clear definition of osteopenia or osteoporosis in children. However, in girls with a previous forearm fracture, Goulding et al observed that for every 1 SD decrease of total body BMD the risk of new fractures at any site doubled during the four years after initial fracture,7 thus supporting the concept that low BMD is the major contributing factor to skeletal fragility.
Known risk factors for low BMD and fragility fractures in children with JIA include the inflammatory process,8 nutrition,9 growth impairment,10 reduced physical activity,9 and treatment, especially corticosteroids.11,12 The risk of osteoporosis can be reduced by ensuring good nutrition,13 encouraging weight bearing exercise,14 and supplementation with calcium and vitamin D.14 In adults, bisphosphonates are an effective treatment for osteoporosis, with studies showing improvements in BMD at the spine and hip and a reduction in fracture risk,15 but there is much less information about their use in children. A recent review of bisphosphonate treatment in children's bone disease showed the potential of these agents,16 but there are long term safety concerns about giving these agents to children,16 particularly with regard to the growing skeleton.17 The aim of this systematic review was to evaluate the currently available evidence for the effectiveness and safety of bisphosphonates, specifically in children with JIA.
Identification of studies
We searched Medline (Ovid 1966 to 2005), Embase (Ovid 1980 to 2005), Cochrane Library, ISI Web of Science (1981 to 2005), and Current Controlled Trials using structured electronic search strategies in the format: (“bisphosphonate”) combined with (“osteoporosis” or “bone mineral density”) and (“children”). We checked bibliographies of identified papers for further studies. For the effectiveness review, all studies (full papers and conference abstracts) including children with JIA or other connective tissue disease treated with bisphosphonates were included. To increase the number of children in the safety review, studies in osteogenesis imperfecta were also included.
Quality assessment and extraction of data
Data extraction and quality assessment forms, that would be suitable for subjective assessment of all types of studies, were developed by the authors for use in this review. As well as methodology and results, issues of bias relevant to a range of study types were addressed (selection, performance, attrition, and detection biases).18 The outcomes of treatment included bone status assessed with densitometry using DXA or other methods; aBMD is calculated by dividing BMC by the scanned area but, based on assumptions about vertebral or hip shape, true volumetric density (g/cm3) or bone mineral apparent density (BMAD) may be estimated. Computed tomography provides a volumetric density (vBMD) but is not widely used given the relatively higher radiation doses involved. Results can be expressed as standardised or “Z‐scores”. The Z‐score is the number of SD an observed measurement is away from the expected value (based on reference data) for age. Other outcome measures were biochemical markers of bone turnover, fracture occurrence, and subjective outcomes such as pain and disability.
Quantitative data analysis was not undertaken because of study heterogeneity. Findings were summarised using tables and narrative synthesis.
Initially, 94 papers were identified and 35 were excluded from the review: low bone mineral density not associated with JIA, connective tissue disease or osteogenesis imperfecta (17 papers), no intervention (five papers), data published elsewhere (four papers), other intervention (three papers), abstracts later published as full studies (three papers), treatment of hypercalcaemia (one paper), review article (one paper), or adult patients (one paper). The case series reported by Cimaz et al19 included children from the cohort study conducted by Bianchi et al, as well as some additional children.
Effectiveness of bisphosphonates
Sixteen papers discussed the use of bisphosphonates in children with JIA (table 11)) or other connective tissue diseases (table 22):): one randomised controlled trial (RCT),20 three controlled cohort studies,21,22,23 11 case series,19,24,25,26,27,28,29,30,31,32,33 and one case report.34
Table thumbnail
Table 1 Bisphosphonate studies in connective tissue disease, including patients with JIA
Table thumbnail
Table 2 Bisphosphonate studies in other connective tissue diseases
Characteristics of children
Seventy eight JIA children could be identified in the 16 effectiveness studies, and five additional children were classified as having corticosteroid induced osteoporosis. Two studies recruited children at risk of low BMD and fractures because of disease and long term corticosteroid treatment.20,26 The remaining studies recruited children with pre‐existing poor bone health; four of these studies required a history of fragility fractures.19,21,23,25
Interventions
The studies evaluated mainly alendronate19,20,21,27,28,32,33 and pamidronate,23,24,25,29,30,34 using a range of different doses, routes of administration, and cycle lengths. In eight studies, all children continued with their usual corticosteroid treatment.19,20,21,23,25,26,27,28 Nine studies ensured that calcium and/or vitamin D intakes were adequate.19,20,21,23,26,28,31,33,34 Follow up was generally for 1–2 years.
Outcomes assessed
All 16 studies assessed bone status ((tablestables 1 and 22).). Children had low BMD at baseline with Z‐scores below the expected values for age and sex matched children. Treatment with bisphosphonates increased bone density compared with baseline: the mean percentage increase in spine BMD ranged from 4.5% to 19.1%.
In the RCT, lumbar spine BMAD increased significantly from baseline in the alendronate treated group (p = 0.013), whereas there was little change in the placebo group.20 Femoral shaft BMAD also increased but was not statistically significant. Bianchi et al recorded a statistically significant mean increase in BMD after one year compared with baseline of 14.9±19.8% (p < 0.002) in treated children; the increase was smaller and non‐significant for untreated children (2.6±6.5%).21 Acott et al reported that treatment with pamidronate resulted in significantly increased spine aBMD Z‐scores compared with baseline.23 The control children had higher baseline Z‐scores compared with the treated children and the Z‐scores decreased during the study. Lepore et al recorded an 8% increase in aBMD of children treated with clodronate for one year compared with a 7% decrease in untreated children.22
Although BMD continued to increase with continued treatment in most studies, the percentage increase declined with time in some studies. For example, there was a mean percentage increase in aBMD of 3.5±6.1% (p = 0.005) after one year of treatment compared with baseline, but after two years the annual change in aBMD was 13.8±11.8% (p = 0.004) and after three years it was 4.5±11.8% (p = 0.05).26
Nine studies with bisphosphonates19,20,21,23,24,25,29,31,34 evaluated the effect of treatment on biochemical markers of bone turnover including markers of bone formation such as osteocalcin and alkaline phosphatase, and markers of bone resorption such as pyridinoline, deoxypyridinoline, and the C‐terminal and N‐terminal cross‐linked telopeptides of type I collagen. Four studies noted changes in these markers which were not consistent across studies,19,20,21,31 whereas five studies noted no significant changes.23,24,25,29,34
Five studies reported the incidence of fractures before and after treatment.20,21,23,25,30 In the RCT, three subjects had sustained fractures before entering but during the study only one patient in the control group sustained a fracture.20 In a second study, 17 children had experienced fracture on entry.23 One of these children had a recurrence of a thoracic vertebral body compression fracture one year after discontinuation of pamidronate. In another study, 10 children had experienced 38 fractures in the year before treatment; 12 of these fractures had been in children with corticosteroid induced osteoporosis.25 Only two fractures occurred in the first year of treatment with pamidronate and none of these were in children with corticosteroid induced osteoporosis. Bianchi et al reported that no new fractures occurred during treatment with alendronate.21 However, they did not report the incidence of fractures before treatment. In the fifth study, three of four children had fractures in both the lumbar and thoracic spine at baseline; there were no further vertebral fractures during the study.30
Improvements in subjective outcomes were also noted, including a progressive reduction in chronic bone pain and disability,24 reduced bone pain and increased strength,25 resolution of back pain,28 and immobilised children became able to walk.29
Review of safety
JIA and connective tissue diseases
Three studies with bisphosphonates reported no side effects in children.27,28,33 Two studies reported gastrointestinal irritation with oral bisphosphonates;21,22 two children discontinued treatment and in one of these children, oesophageal erosions then healed.21 Four studies using intravenous administration of bisphosphonates reported an acute phase reaction or a transient flu‐like reaction (fever, muscle aches, bone pain) after the first infusion; symptoms were generally managed with paracetamol or ibuprofen and did not occur with further infusions.24,25,29,30 Noguera et al observed mild abdominal pain, nausea, and vomiting after the first infusion.24 In subsequent cycles, children received intravenous odansetron before pamidronate and did not experience any further problems. Five studies reported that growth appeared normal during treatment with bisphosphonates.21,25,29,32,34
Osteogenesis imperfecta
Forty three additional papers evaluated the use of bisphosphonates, mainly pamidronate, in children with osteogenesis imperfecta and were included in the safety review.35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77 As in JIA, the most common side effect of intravenous treatment was an acute phase reaction during the first infusion of bisphosphonate. Munns et al observed respiratory distress in four infants with severe osteogenesis imperfecta and pre‐exiting respiratory compromise during their first treatment with intravenous pamidronate.61
Eight studies reported transient decreases in calcium and phosphate levels after treatment with intravenous pamidronate.35,42,50,51,54,58,59,68 No symptoms of hypocalcaemia were reported and calcium levels returned to normal with or without supplementation. Hogler et al77 recorded biochemical hypocalcaemia in 74% of children and hypophosphataemia in 82% of children after the first infusion of zoledronic acid. The decrease in calcium levels became less after the second and third infusions.77 In one study, a girl with slightly increased serum calcium levels at the start of the study developed microcalcifications of the renal papillae after one year of treatment with intravenous pamidronate.43 The calcium levels returned to normal after withdrawal of vitamin D supplements and the microcalcifications started to regress. Three studies noted no changes on renal ultrasound during treatment with intravenous pamidronate.46,47,56
Several studies examined the effects of bisphosphonates on bone re‐modelling and fracture healing. In one study, bone turnover was suppressed to below that of normal children.35 Falk et al55 observed non‐union of a tibial fracture. During pamidronate treatment, Munns et al36 observed significant delays in elective osteotomy site healing but non‐significant delays in fracture healing, compared with before treatment. Two studies noted that fracture healing was not delayed and there were no instances of fracture non‐union.42,70 The linear growth of children was at least normal in four studies.42,47,56,64 Sclerosis occurred at various bone sites which disappeared on discontinuation of treatment with pamidronate.53 There were no effects of commonly used doses of bisphosphonates on the growth plate and the bone ages of children corresponded with their chronological age.42
Two young women received long term pamidronate treatment before conception.66 Pamidronate was stopped after conception; the pregnancies and deliveries were uneventful and both mothers and babies remained well up to 16 months postpartum.
Evidence from the studies included in this review indicates that bisphosphonates may have a role in preventing low BMD and fragility fractures associated with JIA. However, the quality of the studies was variable. Only small numbers of children with JIA were included and studies recruited a mixture of children with JIA and other connective tissue diseases. Only one study reported that they used a standard definition of JIA.21 There was considerable variation in the doses and schedules of bisphosphonates. Some children had been treated with corticosteroids when they entered the study and continued with treatment, others were not. It is possible that concomitant treatment with calcium and/or vitamin D may have affected the outcome, but only nine studies ensured that the children received an adequate calcium and/or vitamin D intake.
Four studies included an intervention group of children treated with bisphosphonates and a control group of children receiving standard treatment.20,21,22,23 However, none of the studies compared directly the results of intervention and control groups; the results were only compared with the group's own baseline. There were also differences in disease severity between groups. Acott et al compared corticosteroid treated children who had experienced fractures with corticosteroid treated children who had not experienced fractures and had greater BMD.23 Similarly, the control group of children recruited by Bianchi et al had less severe disease which did not require corticosteroid therapy and had not experienced fragility fractures.21
The current methods of assessment of treatment outcome all have limitations. Measurement of BMD using DXA was the most widely used outcome measure in these studies but careful interpretation of the results is required.78 DXA estimates BMD as a two‐dimensional ratio of the amount of bone and the area scanned (aBMD) rather than true three‐dimensional density. aBMD increases with bone size because of the greater thickness of larger bones; it underestimates aBMD in small children and overestimates it in larger children and thus may be affected by the child's body size, pubertal stage, and, to a lesser extent, age and ethnic group.78 Several methods are available to adjust aBMD to account for the size of children.78 The observed increase in aBMD after treatment with bisphosphonates may, in part, be caused by changes in bone size related to growth and puberty, but only two studies in the review reported that they adjusted BMD for size,19,21 while two estimated volumetric BMD.20,25 The fact that adjustments may not have been made to account for the size of children undermines the validity of the results and makes it difficult to compare results between studies.
Eight studies examined biochemical markers of bone turnover and noted changes in levels during treatment. However, there is uncertainty about which markers best reflect bone status. In addition, few normative data are available for paediatric bone markers which are affected by age, sex, and puberty.
Both densitometry and bone markers are surrogate outcomes; the outcome of main interest and significance is reduction in fracture occurrence in the subjects as both children and adults. Although only short term studies have been conducted, several showed a reduction in fractures during treatment with bisphosphonates. Longer term studies are needed to show that these effects are sustained.
The review of safety showed that bisphosphonates were generally well tolerated in children. However, there is a report of iatrogenic osteopetrosis after administration of very high doses of intravenous pamidronate for “idiopathic hyperphosphatasia”.79 A major concern has been about long term effects. Although bisphosphonates have anti‐resorptive effects on bone, there was no evidence of adverse long term effects at commonly used doses. Hoekman et al observed that all the biochemical markers of bone turnover returned to pretreatment levels after stopping bisphosphonate treatment, suggesting that there was no permanent inhibition of bone activity.80 Several studies reported that fracture and osteotomy site healing was not delayed. Linear growth was unaffected by treatment. Sclerotic lines have occurred but they faded or disappeared, although a recently published study shows that they can persist for up to 8 years (mean 4 years).81 This study also noted that pamidronate interferes with the process of periosteal resorption, resulting in wider metaphyses.81 There have been concerns that bisphosphonates could be retained in bone then released later in life. Of note, two young women continued treatment with bisphosphonate until conception without untoward effects on themselves or their babies.66 However, because of the different disease pathologies, some care should be taken with the extrapolation of results from the use of bisphosphonates in osteogenesis imperfecta to effects in children with JIA. For example, there are anecdotal reports of bone mineral density increasing with bisphosphonates, but after prolonged treatment the bones were found to be more brittle during spinal surgery.82 There is also concern that bisphosphonates administered at higher doses produce highly mineralised bone that is subject to microfracture damage,83 which might potentially increase the risk of cortical fractures in the long term. The effects of long term accumulation of bisphosphonates in children are unknown.
In conclusion, bisphosphonates are a promising treatment for osteoporosis in children with JIA, but the quality of the current evidence is variable; better studies are needed to support evidence based practice in this patient group. The lack of evidence in this area reflects a wider gap in evidence available to support paediatric prescribing. The recent National Service Framework for Children recommends that children who require ongoing health interventions have access to high quality care.84 This access is reduced by the lack of evidence to support prescribers in providing safe and effective treatments. Recognition of this gap has led to the development of the Medicines for Children Research Network which aims to improve the quality of research in this area (http://www.liv.ac.uk/mcrn/). Studies need to recruit larger numbers of more clearly defined patients. Outcome must be accurately assessed, taking into account both growth of children during the study and any technical limitations of the measures. A recent general review supports our findings that there are still many unanswered questions about the use of bisphosphonates in children.16 The optimum dose and frequency of administration and the length of treatment have not been defined. The maximal bone mass gain that can be achieved is not known and it is not clear whether the positive effects of treatment continue over time. The criteria for initiating treatment need clarifying; should treatment be limited to children with pre‐existing low BMD and/or fractures or include children thought to be at risk of these problems? Finally, future studies should be longer term and include fragility fractures as an outcome. Multicentre studies are more likely to achieve sufficient patient numbers to answer some of these questions about longer term treatment, including the change in fracture incidence.
Finally, more aggressive treatment of JIA with intra‐articular corticosteroids and intravenous corticosteroid pulses may help avoid long term treatment with oral corticosteroids. In addition, increased and earlier use of disease modifying antirheumatic drugs such as methotrexate and cytokine inhibitors such as etanercept and infliximab might reduce the decline in BMD in these children.
 
What is already known on this topic
  • Low bone mineral density and fragility fractures are complications of JIA, persisting into adulthood
  • Bisphosphonates are effective in post‐menopausal osteoporosis and corticosteroid induced osteoporosis in adults, but there are concerns about their effectiveness and long term adverse effects in children
 
What this study adds
  • There are few studies of bisphosphonates in children with JIA overall, and only four comparative studies; the quality of evidence from these studies is variable
  • Bisphosphonates appear to be a promising treatment for low bone mineral density and fragility fractures, but future studies in JIA should have longer follow up and more rigorous assessment of outcome
Abbreviations
aBMD - areal bone mineral density
BMAD - bone mineral apparent density
BMC - bone mineral content
BMD - bone mineral density
DXA - dual energy x ray absorptiometry
JIA - juvenile idiopathic arthritis
Footnotes
Funding: this project was funded by the NHS R&D Programme Health Technology Assessment Programme (03/43/04)
Competing interests: none
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health
1. Burnham J N, Weinstein R, Lewis J D. et al Childhood onset arthritis is associated with an elevated risk of fracture. Abstract 157. American College of Rheumatology Annual Meeting 2005.
2. Zak M, Hassager C, Lovell D J. et al Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross‐sectional long‐term followup study. Arthritis Rheum 1999. 42790–798.798. [PubMed]
3. French A R, Mason T, Nelson A M. et al Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol 2002. 291065–1070.1070. [PubMed]
4. Weinstein R S. True strength. J Bone Miner Res 2000. 15621–625.625. [PubMed]
5. Kanis J A. Diagnosis of osteoporosis. Osteoporos Int 1997. 7(suppl 3)S108–S116.S116. [PubMed]
6. Marshall D, Johnell O, Wedel H. Meta‐analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996. 3121254–1259.1259. [PMC free article] [PubMed]
7. Goulding A, Jones I E, Taylor R W. et al More broken bones: a 4‐year double cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 2000. 152011–2018.2018. [PubMed]
8. Haugen M, Lien G, Flato B. et al Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000. 431504–1510.1510. [PubMed]
9. Kotaniemi A, Savolainen A, Kroger H. et al Weight‐bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999. 2819–26.26. [PubMed]
10. Rooney M, Davies U M, Reeve J. et al Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000. 271073–1081.1081. [PubMed]
11. Perez M D, Abrams S A, Loddeke L. et al Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x‐ray absorptiometry. J Rheumatol 2000. 5838–43.43.
12. Brik R, Keidar Z, Schapira D. et al Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998. 25990–992.992. [PubMed]
13. Henderson C J, Specker B L, Sierra R I. et al Total‐body bone mineral content in non‐corticosteroid‐treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000. 43531–540.540. [PubMed]
14. Kotaniemi A, Savolainen A, Kroger H. et al Weight‐bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999. 2819–26.26. [PubMed]
15. Stevenson M, Lloyd J M, De Nigris E. et al A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005. 91–160.160. [PubMed]
16. Shaw N J, Bishop N J. Bisphosphonate treatment of bone disease. Arch Dis Child 2005. 90494–499.499. [PMC free article] [PubMed]
17. Srivastava T, Alon U S. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003. 162735–751.751. [PubMed]
18. Centre for Reviews and Dissemination Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. 4, 2nd edn. York: University of York, 2001.
19. Cimaz R, Gattorno M, Sormani M P. et al Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002. 291786–1792.1792. [PubMed]
20. Rudge S, Hailwood S, Horne A. et al Effects of once‐weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005. 44813–818.818. [PubMed]
21. Bianchi M L, Cimaz R, Bardare M. et al Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000. 431960–1966.1966. [PubMed]
22. Lepore L, Pennesi M, Barbi E. et al Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991. 9(suppl 6)33–35.35. [PubMed]
23. Acott P D, Wong J A, Lang B A. et al Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005. 20368–373.373. [PubMed]
24. Noguera A, Ros J B, Pavia C. et al Bisphosphonates, a new treatment for glucocorticoid‐induced osteoporosis in children. J Pediatr Endocrinol Metab 2003. 16529–536.536. [PubMed]
25. Gandrud L M, Cheung J C, Daniels M W. et al Low‐dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol 2003. 16887–892.892.
26. Gattinara M, Pontikaki I, Gerloni V. et al Use of cyclic etidronate in patients with juvenile chronic rheumatic diseases receiving long term treatment with steroids. Ann Rheum Dis 2000. 59743–744.744.
27. Bardare M, Grassi A, Dell'Era L. et al Alendronate in the treatment of osteoporosis in rheumatic diseases of childhood. Ann Rheum Dis 2000. 59742.
28. Falcini F, Trapani S, Ermini M. et al Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996. 58166–169.169. [PubMed]
29. Brumsen C, Hamdy N A T, Papapoulos S E. Long‐term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997. 76266–283.283. [PubMed]
30. Shaw N J, Boivin C M, Crabtree N J. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000. 83143–145.145. [PMC free article] [PubMed]
31. Chlebna‐Sokol D, Blaszczyk A, Rusinska A. et al Treatment of osteoporosis and osteopenia in children—own experience. Przegl Lek 2003. 605–11.11.
32. Fernandes J L, Viana S L, Rocha A L. et al Biphosphonate‐induced radiographic changes in two pediatric patients with rheumatic diseases. Skeletal Radiol 2004. 33732–736.736. [PubMed]
33. Bayer M, Stepan J, Kutilek S. Alendronate in treatment of osteoporosis in childhood. Osteologicky Bulletin 2002. 723–24.24.
34. Oliveri M B, Palermo R, Mautalen C. et al Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996. 232152–2155.2155. [PubMed]
35. Rauch F, Plotkin H, Travers R. et al Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003. 88986–992.992. [PubMed]
36. Munns C F, Rauch F, Zeitlin L. et al Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004. 191779–1786.1786. [PubMed]
37. Zeitlin L, Rauch F, Plotkin H. et al Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003. 1111030–1036.1036. [PubMed]
38. Rauch F, Plotkin H, Zeitlin L. et al Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003. 18610–614.614. [PubMed]
39. Rauch F, Travers R, Plotkin H. et al The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002. 1101293–1299.1299. [PMC free article] [PubMed]
40. Montpetit K, Plotkin H, Rauch F. et al Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003. 111e601–e603.e603. [PubMed]
41. Grissom L E, Harcke H T. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003. 33226–229.229. [PubMed]
42. Glorieux F H, Bishop N J, Plotkin H. et al Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998. 339947–952.952. [PubMed]
43. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002. 86356–364.364. [PMC free article] [PubMed]
44. Arikoski P, Silverwood B, Tillmann V. et al Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual‐energy X‐ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004. 34539–546.546. [PubMed]
45. Robinson R F, Nahata M C, Hayes J R. et al Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 2004. 24195–197.197. [PubMed]
46. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 2004. 171511–1517.1517. [PubMed]
47. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta—lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002. 15163–174.174. [PubMed]
48. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single‐day intravenous pamidronate infusions. J Pediatr 2003. 142417–423.423. [PubMed]
49. Bin‐Abbas B S, Al Ashwal A A, Al Zayed Z S. et al Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta. Saudi Medical Journal 2004. 251772–1773.1773. [PubMed]
50. Banerjee I, Shortland G J, Evans W D. et al Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002. 87562–563.563. [PMC free article] [PubMed]
51. Dimeglio L A, Ford L, McClintock C. et al Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004. 351038–1045.1045. [PubMed]
52. Plotkin H, Rauch F, Bishop N J. et al Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000. 851846–1850.1850. [PubMed]
53. van Persijn van Meerten E L, Kroon H M, Papapoulos S E. Epi‐ and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992. 184249–254.254. [PubMed]
54. Giraud F, Meunier P J. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open‐label study in seven patients. Joint, Bone, Spine: Revue du Rhumatisme 2002. 69486–490.490.
55. Falk M J, Heeger S, Lynch K A. et al Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003. 111573–578.578. [PubMed]
56. Lee Y S, Low S L, Lim L A. et al Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001. 160641–644.644. [PubMed]
57. Bishop N J, Lanoue G, Chabot G. et al Clinical and bone densitometric improvement after pamidronate infusion in children with severe osteogenesis imperfecta. J Bone Miner Res 1996. 11S251.
58. Huzjak N, Barisic I, Resic A. et al Our experience in the treatment of osteogenesis imperfecta with bisphosphates. Paediatria Croatica 2002. 4655–59.59.
59. Fujiwara I, Ogawa E, Igarashi Y. et al Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998. 157261–262.262. [PubMed]
60. Sumnik Z, Land C, Rieger‐Wettengl G. et al Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis: a pilot study using radiographic morphometry. Horm Res 2004. 61137–142.142. [PubMed]
61. Munns C F, Rauch F, Mier R J. et al Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004. 35231–234.234. [PubMed]
62. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998. 8764–68.68. [PubMed]
63. Gonzalez E, Pavia C, Ros J. et al Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001. 14529–533.533. [PubMed]
64. Bembi B, Parma A, Bottega M. et al Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997. 131622–625.625. [PubMed]
65. Roldan E J A, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 1999. 12555–559.559. [PubMed]
66. Munns C F, Rauch F, Ward L. et al Maternal and fetal outcome after long‐term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004. 191742–1745.1745. [PubMed]
67. Guillot M, Eckart P, Desrosieres H. et al Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report. Arch Pediatr 2001. 8172–175.175. [PubMed]
68. Chien Y H, Chu S Y, Hsu C C. et al Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002. 25593–595.595. [PubMed]
69. Devogelaer J P, Nagant de Deuxchaisnes C, Malghem J. et al Cyclical intermittent therapy with APD in a child with osteogenesis imperfecta: a 3‐year follow‐up of 7 cycles. Evidence of fading away of the oldest radio‐opaque bands. In: Christiansen C, Overgaard K, eds. Osteoporosis. Aalborg: Handelstrykkeriet Aalborg ApS, 1990. 1515–1517.1517.
70. Huaux J P, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988. 871–72.72. [PubMed]
71. Devogelaer J P, Malghem J, Maldague B. et al Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987. 16360–363.363. [PubMed]
72. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003. 92452–455.455. [PubMed]
73. Shaw N J. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child 1997. 7792–93.93. [PMC free article] [PubMed]
74. Sakkers R, Kok D, Engelbert R. et al Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet 2004. 3631427–1431.1431. [PubMed]
75. Landsmeer‐Beker E A, Massa G G, Maaswinkel‐Mooy P D. et al Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997. 156792–794.794. [PubMed]
76. Ashford R U, Dey A, Kayan K. et al Oral clodronate as treatment of osteogenesis imperfecta. Arch Dis Child 2003. 88945.
77. Hogler W, Yap F, Little D. et al Short‐term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004. 145701–704.704. [PubMed]
78. Fewtrell M S., British Paediatric & Adolescent Bone Group Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child 2003. 88795–798.798. [PMC free article] [PubMed]
79. Whyte M P, Wenkert D, Clements K L. et al Bisphosphonate‐induced osteopetrosis. N Engl J Med 2003. 349457–463.463. [PubMed]
80. Hoekman K, Papapoulos S E, Peters A C. et al Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985. 61952–956.956. [PubMed]
81. Land C, Rauch F, Glorieux F H. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006. 21374–379.379. [PubMed]
82. Marini J C. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003. 349423–426.426. [PubMed]
83. Mashiba T, Turner C H, Hirano T. et al Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001. 28524–531.531. [PubMed]
84. Department of Health National Service Framework for Children, Young People and Maternity Services. London: Department of Health, 2004.
Articles from Archives of Disease in Childhood are provided here courtesy of
BMJ Group